Benjamin Durham researcher
Durham, Benjamin H.
VIAF ID: 1154380859530290228 (Personal)
Permalink: http://viaf.org/viaf/1154380859530290228
Preferred Forms
- 100 0 _ ‡a Benjamin Durham ‡c researcher
- 100 1 _ ‡a Durham, Benjamin H.
4xx's: Alternate Name Forms (6)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. | |
Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease | |
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. | |
The clinical spectrum of Erdheim-Chester disease: an observational cohort study | |
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. | |
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. | |
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling | |
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. | |
Efficacy of MEK inhibition in patients with histiocytic neoplasms | |
Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells | |
A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1 | |
Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis | |
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. | |
Histiocytic neoplasms in the era of personalized genomic medicine | |
The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. | |
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas | |
Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene | |
Loss of BAP1 function leads to EZH2-dependent transformation | |
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition | |
miR-99 regulates normal and malignant hematopoietic stem cell self-renewal. | |
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins | |
Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages. | |
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis | |
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells | |
Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. | |
Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. | |
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies | |
Rapidly progressive primary leptomeningeal atypical teratoid/rhabdoid tumor: a report of 2 cases. | |
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". | |
Resistant Fusarium keratitis progressing to endophthalmitis | |
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. | |
Single-agent dabrafenib for BRAFV600E-mutated histiocytosis. | |
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. | |
Sonographic appearance of a dermoid cyst (mature cystic teratoma) of the spleen | |
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations |